New Italian study below.
Those who have followed my posts touching on the issue of MetS & PCa might be wondering why this kind of study would still be required in 2017.
PCa is usually described as a hormonal cancer, although there is no evidence that it is actually caused by normal levels of testosterone. The connection between PCa risk & CVD risk has long been recognized, but very few doctors would describe PCa as being part of a metabolic disorder.
"Links between metabolic syndrome and prostate cancer after androgen deprivation therapy are emerging." This is exasperating. Men on ADT - & their doctors - are well aware of the consequences (not side effects!) of ADT.
"The aim of the research was to investigate the association of metabolic syndrome and aggressive prostate malignancy, at initial diagnosis, without the influence of hormonal treatment.
"Metabolic syndrome was significantly associated with aggressive prostate cancer" Risk factor = 1.87.
"In our study, patients with metabolic syndrome were more likely to present with more aggressive prostate carcinoma vs. patients without metabolic syndrome."
Addressing MetS in new PCa cases might slow progression.
Regardless of biopsy results, MetS should be treated. This might be very important for men on active surveillance, where 25-30% are expected to progress.
{How many of our doctors read the Hormone and Metabolic Research journal, I wonder?}
-Patrick
ncbi.nlm.nih.gov/pubmed/284...
Horm Metab Res. 2017 May 11. doi: 10.1055/s-0043-109866. [Epub ahead of print]
Metabolic Syndrome and Aggressive Prostate Cancer at Initial Diagnosis.
Di Francesco S1, Tenaglia RL1.
Author information
Abstract
Links between metabolic syndrome and prostate cancer after androgen deprivation therapy are emerging. The aim of the research was to investigate the association of metabolic syndrome and aggressive prostate malignancy, at initial diagnosis, without the influence of hormonal treatment. Retrospective analysis of 133 patients with prostate tumor diagnosis between 2007 and 2009 was conducted. Patients with prostate cancer were subdivided in 2 groups according to Gleason score: Gleason score≥7 as high-grade prostate tumor (Group 1) and <7 (Group 2) as low-grade prostate tumor. Metabolic syndrome was defined according to International Diabetes Federation and the American Heart Association/National Heart, Lung, and Blood Institute definition. Metabolic syndrome was significantly associated with aggressive prostate cancer (OR 1.87, p<0.05) and a reduced risk of low-grade prostate cancer (OR 0.53, p<0.05) at initial diagnosis, without the influence of endocrine therapy. In our study, patients with metabolic syndrome were more likely to present with more aggressive prostate carcinoma vs. patients without metabolic syndrome. Further research should elucidate these relations in larger samples to confirm these associations and to stabilize future prevention and therapeutic strategies.
© Georg Thieme Verlag KG Stuttgart · New York.
PMID: 28494504 DOI: 10.1055/s-0043-109866
